Validated spectrofluorimetric method for determination of cyproheptadine in pharmaceutical formulation and human plasma. Application to content uniformity test

Abstract

Cyproheptadine is a first generation antihistaminic drug which has several pharmacological effects includes anesthetic, antiserotonergic and anticholinergic properties. Due to its wide therapeutic use, a cost effective, highly sensitive and simple fluorimetric approach has been developed for estimation of cyproheptadine in its pure forms, commercial tablet and spiked human plasma. Proposed approach is relied simply on binary complex formation of cyproheptadine with eosin in buffered media (pH 4.2). The formed complex lead to quantitative quenching of eosin emission at 538 nm followed the excitation at 335 nm. Proposed approach is characterized by wide linear range from 200 up to 1000 ng/mL with a very high sensitivity (limits of detection and quantitation were 30.91 and 93.6 ng/mL, respectively). Furthermore, the proposed spectrofluorimetric protocol could be utilized for estimation of cyproheptadine in its commercial tablets and spiked human plasma with acceptable accuracy and good precision as all Relative standard deviation values were less than 2. Furthermore, the proposed approach is successfully applied to content uniformity testing of cyproheptadine in commercially available tablets with acceptance value of 2.834. Comparison with reference method revealed no impactful difference in regards to precision or accuracy. As the proposed method could be consider simple, highly sensitive, cost effective and green, it is ideally recommended for quantitative estimation of cyproheptadine in different quality control laboratories.

Keywords

• Spectrofluorimetry
• Cyproheptadine
• Eosin
• Human plasma